| Case Name |
Date Filed |
Judge |
Drug |
Patent No(s). |
| Altaire Pharms., Inc. v. Paragon Bioteck, Inc., 17-1837 (E.D.N.Y.) |
Mar. 31, 2017 |
Hon. William F. Kuntz, II |
phenylephrine HCl ophthalmic solution |
8,859,623 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-0365 (D. Del.) |
Apr. 3, 2017 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen for injection) |
9,399,012 6,992,218 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-1521 (E.D. Pa.) |
Apr. 4, 2017 |
Hon. Jeffrey L. Schmehl |
Ofirmev® (acetaminophen for injection) |
9,399,012 6,992,218 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01100 (PTAB) |
Apr. 4, 2017 |
N/A |
Abraxane® (paclitaxel for injection) |
8,853,260 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01101 (PTAB) |
Apr. 4, 2017 |
N/A |
Abraxane® (paclitaxel for injection) |
7,820,788 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01103 (PTAB) |
Apr. 4, 2017 |
N/A |
Abraxane® (paclitaxel for injection) |
7,923,536 |
| Actavis LLC v. Abraxis Bioscience, LLC, IPR2017-01104 (PTAB) |
Apr. 4, 2017 |
N/A |
Abraxane® (paclitaxel for injection) |
8,138,229 |
| Bristol-Myers Squibb Co. v. Aurobindo Pharma USA Inc., 17-0374 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Breckenridge Pharm., Inc., 17-0375 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Hetero USA Inc., 17-0376 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Invagen Pharms., Inc., 17-0377 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Lupin Ltd., 17-0378 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Mylan Pharms. Inc., 17-0379 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sunshine Lake Pharma Co., Ltd., 17-0380 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Torrent Pharms. Ltd., 17-0381 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Unichem Labs., Ltd., 17-0382 (D. Del.) |
Apr. 5, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Gilead Sciences, Inc. v. Amneal Pharms., LLC, 17-2335 (D.N.J.) |
Apr. 6, 2017 |
Hon. Michael A. Shipp |
Truvada® (emtricitabine / tenofovir disoproxil fumarate tablets) |
6,642,245 6,703,396 8,716,264 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 17-0389 (D. Del.) |
Apr. 7, 2017 |
Hon. Richard G. Andrews |
Afinitor Disperz® (everolimus tablets) |
5,665,772 8,778,962 8,617,598 |
| Purdue Pharma L.P. v. Intellipharmaceutics Int’l Inc., 17-0392 (D. Del.) |
Apr. 7, 2017 |
Hon. Richard G. Andrews |
OxyContin® (oxycodone hydrochloride extended-release tablets) |
9,060,976 9,073,933 9,522,919 9,492,389 9,492,391 8,309,060 |
| Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 17-0393 (D. Del.) |
Apr. 7, 2017 |
Hon. Richard G. Andrews |
Afinitor® (everolimus tablets) |
9,006,224 8,410,131 8,778,962 8,436,010 |
| Dexcel Pharma Technologies Ltd. v. Apotex Corp., 17-2423 (D.N.J.) |
Apr. 7, 2017 |
Hon. Susan D. Wigenton |
omeprazole delayed-release tablets |
9,023,391 7,255,878 |
| Shire-NPS Pharms., Inc. v. Ambio, Inc., 17-0397 (D. Del.) |
Apr. 10, 2017 |
Hon. Gregory M. Sleet |
Gattex® (teduglutide for Injection) |
7,056,886 7,847,061 9,060,992 |
| Bristol-Myers Squibb Co. v. Accord Healthcare Inc., 17-0398 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Apotex, Inc., 17-0399 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 6,413,980 |
| Bristol-Myers Squibb Co. v. Bionpharma Inc., 17-0400 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Dr. Reddy’s Labs., Ltd., 17-0401 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Emcure Pharms. Ltd., 17-0402 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Impax Labs., Inc., 17-0403 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Indoco Remedies Ltd., 17-0404 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Macleods Pharms. Ltd., 17-0405 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Micro Labs USA Inc., 17-0406 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sandoz Inc., 17-0407 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sigmapharm Labs., LLC, 17-0408 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Bristol-Myers Squibb Co. v. Sun Pharm. Indus. Inc., 17-0409 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Teva Pharms. USA, Inc., 17-0410 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Wockhardt Bio AG, 17-0411 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Bristol-Myers Squibb Co. v. Zydus Pharms. (USA) Inc., 17-0412 (D. Del.) |
Apr. 10, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| AstraZeneca Pharms. LP v. Teva Pharms. USA, Inc., 17-2448 (D.N.J.) |
Apr. 10, 2017 |
Hon. Renee Marie Bumb |
Faslodex® (fulvestrant for injection) |
6,774,122 7,456,160 8,329,680 8,466,139 |
| Jazz Pharms., Inc. v. Amneal Pharms. LLC, 17-2452 (D.N.J.) |
Apr. 10, 2017 |
Hon. Esther Salas |
Xyrem® (sodium oxybate oral solution) |
9,539,330 |
| Novartis Pharms. Corp. v. Mylan Pharms. Inc., 17-0054 (N.D.W.V.) |
Apr. 10, 2017 |
Hon. Irene M. Keeley |
Afinitor Disperz® (everolimus tablets) |
5,665,772 8,778,962 8,617,598 |
| Celgene Corp. v. Zydus Pharms. (USA) Inc., 17-2528 (D.N.J.) |
Apr. 12, 2017 |
Hon. Susan D. Wigenton |
Revlimid® (lenalidomide capsules) |
7,465,800 7,855,217 7,968,569 8,530,498 8,648,095 9,101,621 9,101,622 |
| Bristol-Myers Squibb Co. v. Mylan Pharms. Inc., 17-0055 (N.D.W.V.) |
Apr. 12, 2017 |
Hon. Irene M. Keeley |
Eliquis® (apixaban tablets) |
6,967,208 9,326,945 |
| Novartis Pharms. Corp. v. Breckenridge Pharm., Inc., 17-0420 (D. Del.) |
Apr. 13, 2017 |
Hon. Richard G. Andrews |
Affinitor® (everolimus tablets) |
5,665,772 8,410,131 8,778,962 |
| Millennium Pharms., Inc. v. Amneal Pharms. LLC, 17-0422 (D. Del.) |
Apr. 13, 2017 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib for injection) |
6,713,446 6,958,319 |
| Millennium Pharms., Inc. v. Zydus Pharms. (USA) Inc., 17-0423 (D. Del.) |
Apr. 13, 2017 |
Hon. Gregory M. Sleet |
Velcade® (bortezomib for injection) |
6,713,446 6,958,319 |
| Bristol-Myers Squibb Co. v. Prinston Pharm. Inc., 17-0426 (D. Del.) |
Apr. 13, 2017 |
Hon. Leonard P. Stark |
Eliquis® (apixaban tablets) |
9,326,945 |
| Eli Lilly and Co. v. Dr. Reddy’s Labs., Inc., 17-2541 (D.N.J.) |
Apr. 13, 2017 |
Hon. Kevin McNulty |
Cialis® (tadalafil tablets) |
6,943,166 |
| Sucampo AG v. Amneal Pharms. LLC, 17-2577 (D.N.J.) |
Apr. 13, 2017 |
Hon. Peter G. Sheridan |
Amitiza® (lubiprostone capsules) |
6,982,283 8,097,653 8,389,542 8,026,393 8,338,639 |
| Eli Lilly and Co. v. Par Pharm., Inc., 17-1219 (S.D. Ind.) |
Apr. 18, 2017 |
Hon. William T. Lawrence |
Axiron® (testosterone metered transdermal solution) |
8,435,944 8,993,520 9,180,194 8,419,307 8,177,449 8,807,861 9,289,586 |
| AstraZeneca Pharms. LP v. HBT Labs., Inc., 17-2652 (D.N.J.) |
Apr. 18, 2017 |
Hon. Renee Marie Bumb |
Faslodex® (fulvestrant for injection) |
6,774,122 7,456,160 8,329,680 8,466,139 |
| Par Pharm., Inc. v. Sumitomo Dainippon Pharma Co., Ltd., IPR2017-01292 (PTAB) |
Apr. 18, 2017 |
N/A |
Latuda® (lurasidone hydrochloride tablets) |
9,555,027 |
| Ferring Pharms. Inc. v. Teva Pharms. USA, Inc., 17-0435 (D. Del.) |
Apr. 19, 2017 |
Hon. Richard G. Andrews |
Prepopik® (sodium picosulfate / magnesium oxide / citric acid oral solution) |
8,450,338 8,481,083 |
| Meda Pharms. Inc. v. Akorn, Inc., 17-0439 (D. Del.) |
Apr. 19, 2017 |
Hon. Gregory M. Sleet |
Astepro® (azelastine HCl nasal spray) |
8,071,073 8,518,919 |
| Onyx Therapeutics, Inc. v. Teva Pharms. USA, Inc., 17-0449 (D. Del.) |
Apr. 20, 2017 |
Hon. Leonard P. Stark |
Kyprolis® (carfilzomib for injection) |
7,417,042 7,232,818 7,491,704 7,737,112 8,129,346 8,207,125 8,207,126 8,207,127 8,207,297 |
| Purdue Pharma L.P. v. Abhai, LLC, 17-0450 (D. Del.) |
Apr. 20, 2017 |
Hon. Richard G. Andrews |
OxyContin® (oxycodone HCl extended-release tablets) |
9,492,389 9,492,391 9,492,392 9,492,393 9,522,919 |
| Amneal Pharms. LLC v. Pfizer Inc., 17-0454 (D. Del.) |
Apr. 20, 2017 |
Vacant Judgeship (2017) |
Zithromax® (azithromycin oral suspension) |
6,268,489 |
| Eli Lilly and Co. v. Par Pharm., Inc., 17-0456 (D. Del.) |
Apr. 21, 2017 |
Hon. Leonard P. Stark |
Axiron® (testosterone metered transdermal solution) |
8,435,944 8,993,520 9,180,194 8,419,307 8,177,449 8,807,861 9,289,586 |
| Bayer Intellectual Property GMBH v. Taro Pharm. Indus. Ltd., 17-0462 (D. Del.) |
Apr. 21, 2017 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Purdue Pharms. LP v. Collegium Pharm., Inc., 17-10690 (D. Mass.) |
Apr. 21, 2017 |
Hon. F. Dennis Saylor, IV |
OxyContin® (oxycodone HCl extended-release tablets) |
9,522,919 |
| Otsuka Pharm. Co., Ltd. v. Zydus Pharms. USA Inc., 17-2754 (D.N.J.) |
Apr. 21, 2017 |
Hon. Jerome B. Simandle |
Abilify® (aripiprazole tablets) |
9,359,302 |
| Allergan Sales, LLC v. Teva Pharms. USA, Inc., 17-0343 (E.D. Tex.) |
Apr. 21, 2017 |
Hon. Rodney Gilstrap |
Delzicol® (mesalamine delayed-release capsules) |
6,649,180 |
| Galderma Labs., L.P. v. Actavis Labs UT, Inc., 17-1076 (N.D. Tex.) |
Apr. 21, 2017 |
Hon. Barbara M.G. Lynn |
Soolantra® (ivermectin cream) |
8,362,069 8,815,816 9,089,587 9,233,117 9,233,118 |
| Adapt Pharma Operations Ltd. v. Teva Pharms. USA, Inc., 17-2877 (D.N.J.) |
Apr. 26, 2017 |
Hon. Jose L. Linares |
Narcan® (naloxone HCl nasal spray) |
9,561,177 |
| Ferring Pharms. Inc. v. Serenity Pharms., LLC, 17-0479 (D. Del.) |
Apr. 28, 2017 |
Hon. Gregory M. Sleet |
Noctiva® (desmopressin acetate nasal spray) |
7,405,203 7,579,321 7,799,761 |
| Bayer Intellectual Property GMBH v. Aurobindo Pharma Ltd., 17-0483 (D. Del.) |
Apr. 28, 2017 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Celgene Corp. v. Par Pharm., Inc., 17-3159 (D.N.J.) |
4-May-17 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
8,198,262 8,673,939 8,735,428 8,828,427 |
| Helsinn Healthcare S.A. v. Virtus Pharms., LLC, 17-3216 (D.N.J.) |
4-May-17 |
Hon. Mary L. Cooper |
Aloxi® (palonosetron HCl for injection) |
7,947,724 7,947,725 7,960,424 8,598,219 8,729,094 |
| Depomed, Inc. v. Strides Pharma, Inc., 17-3180 (D.N.J.) |
5-May-17 |
Hon. Jose L. Linares |
Zipsor® (diclofenac potassium capsules) |
7,662,858 7,884,095 7,939,518 8,110,606 8,623,920 9,561,200 |
| Takeda Pharm. Co. Ltd. v. Torrent Pharms. Ltd., 17-3186 (D.N.J.) |
5-May-17 |
Hon. Stanley R. Chesler |
Nesina® (alogliptin benzoate tablets) Oseni® (alogliptin benzoate / pioglitazone HCl tablets) Kazano® (alogliptin benzoate / metformin HCl tablets) |
7,807,689 8,173,663 8,288,539 8,900,638 |
| Rhodes Pharms. L.P. v. Ascent Pharms. Inc., 17-2755 (E.D.N.Y.) |
5-May-17 |
Hon. Pamela K. Chen |
Dilaudid® (hydromorphone HCl oral solution) |
6,589,960 |
| Astellas Pharma Inc. v. Roxane Labs., Inc., 17-0542 (D. Del.) |
9-May-17 |
Hon. Gregory M. Sleet |
Xtandi® (enzalutamide capsules) |
7,709,517 8,183,274 9,126,941 |
| Impax Labs., Inc. v. Actavis Labs. FL, Inc., 17-3295 (D.N.J.) |
9-May-17 |
Hon. Stanley R. Chesler |
Rytary® (levodopa / carbidopa capsules) |
9,533,046 |
| Horizon Pharma Ireland Ltd. v. Actavis Labs. UT, Inc., 17-3342 (D.N.J.) |
11-May-17 |
Hon. Noel L. Hillman |
Pennsaid® (diclofenac sodium topical solution) |
9,539,335 |
| Celgene Corp. v. Hetero Labs Ltd., 17-3387 (D.N.J.) |
11-May-17 |
Hon. Esther Salas |
Pomalyst® (pomalidomide capsules) |
8,198,262 8,673,939 8,735,428 8,828,427 |
| Novo Nordisk Inc. v. Glenmark Pharms. Ltd., 17-3462 (D.N.J.) |
11-May-17 |
Hon. Michael A. Shipp |
Vagifem® (estradiol vaginal tablets) |
7,018,992 |
| Bayer Intellectual Property GMBH v. Micro Labs Ltd., 17-0560 (D. Del.) |
12-May-17 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Argentum Pharms. LLC v. Kaken Pharm. Co., Ltd., IPR2017-01429 (PTAB) |
12-May-17 |
N/A |
Jublia® (efinaconazole topical solution) |
7,214,506 |
| Micro Labs Ltd. v. Santen Pharm. Co., Ltd., IPR2017-01434 (PTAB) |
12-May-17 |
N/A |
Zioptan® (tafluprost ophthalmic solution) |
5,886,035 |
| Taro Pharms. U.S.A., Inc. v. Apotex Technologies, Inc., IPR2017-01446 (PTAB) |
17-May-17 |
N/A |
Ferriprox® (deferiprone oral solution/tablets) |
7,049,328 |
| Bayer Intellectual Property GMBH v. Mylan Pharms. Inc., 17-0584 (D. Del.) |
19-May-17 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Genzyme Corp. v. Ingenus Pharms. LLC, 17-0602 (D. Del.) |
24-May-17 |
Hon. Leonard P. Stark |
Clolar® (clofarabine for injection) |
5,661,136 |
| Acorda Therapeutics, Inc. v. Micro Labs Ltd., 17-3724 (D.N.J.) |
24-May-17 |
Hon. Brian R. Martinotti |
Ampyra® (dalfampridine extended-release tablets) |
8,007,826 8,354,437 8,440,703 8,663,685 |
| Bayer Intellectual Property GMBH v. Sigmapharm Labs., LLC, 17-0648 (D. Del.) |
26-May-17 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Upsher-Smith Labs., Inc. v. Glenmark Pharms. Ltd., 17-0649 (D. Del.) |
26-May-17 |
Vacant Judgeship (2017) |
Qudexy® XR (topiramate extended-release capsules) |
8,652,527 8,889,190 9,101,545 9,555,005 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-0660 (D. Del.) |
31-May-17 |
Hon. Leonard P. Stark |
Ofirmev® (acetaminophen for injection) |
9,399,012 9,610,265 |
| Allergan Inc. v. Taro Pharm. Industries Ltd., 17-0663 (D. Del.) |
1-Jun-17 |
Vacant Judgeship (2017) |
Aczone® (dapsone gel) |
9,517,219 |
| Osi Pharms., LLC v. Hetero USA Inc., 17-0665 (D. Del.) |
1-Jun-17 |
Hon. Gregory M. Sleet |
Tarceva® (erlotinib HCl tablets) |
6,900,221 |
| Osi Pharms., LLC v. Sun Pharms. Industries Inc., 17-0666 (D. Del.) |
1-Jun-17 |
Hon. Gregory M. Sleet |
Tarceva® (erlotinib HCl tablets) |
6,900,221 |
| Forest Labs., LLC v. Macleods Pharms., Ltd., 17-0672 (D. Del.) |
2-Jun-17 |
Hon. Leonard P. Stark |
Namenda XR® (memantine HCl extended-release capsules) |
8,039,009 8,168,209 8,173,708 8,283,379 |
| Forest Labs., LLC v. Macleods Pharms., Ltd., 17-0673 (D. Del.) |
2-Jun-17 |
Hon. Leonard P. Stark |
Namzaric® (memantine HCl / donepezil HCl extended-release capsules) |
8,039,009 8,058,291 8,338,485 8,338,486 8,580,858 |
| Mallinckrodt IP v. B. Braun Medical Inc., 17-2474 (E.D. Pa.) |
2-Jun-17 |
Hon. Jeffrey L. Schmehl |
Ofirmev® (acetaminophen for injection) |
9,399,012 9,610,265 |
| Purdue Pharma L.P. v. Alvogen Pine Brook, LLC, 17-0677 (D. Del.) |
5-Jun-17 |
Hon. Gregory M. Sleet |
Hysingla® ER (hydrocodone bitartrate extended-release tablets) |
9,486,412 9,486,413 9,492,389 9,492,390 9,492,391 9,545,380 9,517,236 9,572,779 9,572,804 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01526 (PTAB) |
5-Jun-17 |
N/A |
Lantus® (insulin glargine recombinant for injection) |
7,476,652 |
| Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland GMBH, IPR2017-01528 (PTAB) |
5-Jun-17 |
N/A |
Lantus® (insulin glargine recombinant for injection) |
7,713,930 |
| Pfizer Inc. v. Macleods Pharms., Ltd., 17-0683 (D. Del.) |
6-Jun-17 |
Hon. Richard G. Andrews |
Viagra® (sildenafil citrate tablets) |
6,469,012 |
| Amgen Inc. v. Piramal Healthcare UK Ltd., 17-0713 (D. Del.) |
9-Jun-17 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet HCl tablets) |
9,375,405 |
| AstraZeneca LP v. Apotex Inc., 17-0714 (D. Del.) |
9-Jun-17 |
Hon. Richard G. Andrews |
Brilinta® (ticagrelor tablets) |
RE46,276 7,250,419 7,265,124 |
| Argentum Pharms. LLC v. Novartis A.G., IPR2017-01550 (PTAB) |
9-Jun-17 |
N/A |
Gilenya® (fingolimod capsules) |
9,187,405 |
| Par Pharm., Inc. v. MonoSol Rx, LLC, IPR2017-01557 (PTAB) |
9-Jun-17 |
N/A |
Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) |
8,603,514 |
| Noden Pharma DAC v. Anchen Pharms., Inc., 17-0728 (D. Del.) |
12-Jun-17 |
Vacant Judgeship (2017) |
Tekturna® (aliskiren hemifumarate tablets) |
8,617,595 |
| Kowa Co., Ltd. v. Hetero Drugs Ltd., 17-4421 (S.D.N.Y.) |
12-Jun-17 |
Hon. Paul A. Crotty |
Livalo® (pitavastatin calcium tablets) |
8,557,993 |
| Dr. Reddy’s Labs. S.A. v. MonoSol Rx, LLC, IPR2017-01582 (PTAB) |
12-Jun-17 |
N/A |
Suboxone® (buprenorphine HCl / naloxone HCl sublingual film) |
8,603,514 |
| Breckenridge Pharm., Inc. v. Novartis Pharms. Corp., IPR2017-01592 (PTAB) |
12-Jun-17 |
N/A |
Afinitor® (everolimus tablets) |
8,410,131 |
| Orexo AB v. Actavis Elizabeth LLC, 17-0758 (D. Del.) |
14-Jun-17 |
Hon. Gregory M. Sleet |
Zubsolv® (buprenorphine HCl / naloxone HCl dehydrate sublingual tablets) |
9,259,421 8,940,330 |
| Kowa Co., Ltd. v. Hetero Drugs Ltd., 17-0762 (D. Del.) |
14-Jun-17 |
Hon. Gregory M. Sleet |
Livalo® (pitavastatin calcium tablets) |
8,557,993 |
| Cosmo Technologies Ltd. v. Sun Pharm. Industries, Ltd., 17-4393 (D.N.J.) |
15-Jun-17 |
Hon. Peter G. Sheridan |
Uceris® (budesonide extended-release tablets) |
9,320,716 |
| Belcher Pharms., LLC v. Hospira, Inc., 17-0775 (D. Del.) |
19-Jun-17 |
Hon. Leonard P. Stark |
Abboject® (epinephrine for injection) |
9,283,197 |
| Omeros Corp. v. Sandoz Inc., 17-0799 (D. Del.) |
21-Jun-17 |
Hon. Richard G. Andrews |
Omidria® (phenylephrine / ketorolac for injection) |
8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Omeros Corp. v. Sandoz Inc., 17-4564 (D.N.J.) |
21-Jun-17 |
Hon. Brian R. Martinotti |
Omidria® (phenylephrine / ketorolac for injection) |
8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Watson Labs., Inc. v. United Therapeutics, Inc., IPR2017-01621 (PTAB) |
21-Jun-17 |
N/A |
Tyvaso® (treprostinil solution for inhalation) |
9,358,240 |
| Watson Labs., Inc. v. United Therapeutics, Inc., IPR2017-01622 (PTAB) |
21-Jun-17 |
N/A |
Tyvaso® (treprostinil solution for inhalation) |
9,339,507 |
| Omeros Corp. v. Lupin Ltd., 17-0803 (D. Del.) |
22-Jun-17 |
Hon. Richard G. Andrews |
Omidria® (phenylephrine / ketorolac for injection) |
8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Omeros Corp. v. Lupin Ltd., 17-4595 (D.N.J.) |
22-Jun-17 |
Hon. Brian R. Martinotti |
Omidria® (phenylephrine / ketorolac for injection) |
8,173,707 8,586,633 9,066,856 9,278,101 9,399,040 9,486,406 |
| Aurobindo Pharma USA Inc. v. Andrx Corp., IPR2017-01648 (PTAB) |
22-Jun-17 |
N/A |
Fortamet® (metformin HCl extended-release tablets) Actoplus® Met XR (metformin HCl / pioglitazone HCl extended-release tablets) |
6,866,866 |
| Teijin Ltd. v. Indoco Remedies Ltd., 17-0809 (D. Del.) |
23-Jun-17 |
Vacant Judgeship (2017) |
Uloric® (febuxostat tablets) |
7,361,676 8,372,872 9,107,912 |
| Bayer Intellectual Property GMBH v. Invagen Pharms., Inc., 17-0812 (D. Del.) |
23-Jun-17 |
Hon. Richard G. Andrews |
Xarelto® (rivaroxaban tablets) |
9,539,218 |
| Amgen Inc. v. Alkem Labs. Ltd., 17-0815 (D. Del.) |
23-Jun-17 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet HCl tablets) |
9,375,405 |
| Amgen Inc. v. Lupin Ltd., 17-0816 (D. Del.) |
23-Jun-17 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet HCl tablets) |
9,375,405 |
| Amgen Inc. v. Macleods Pharms., Ltd., 17-0817 (D. Del.) |
23-Jun-17 |
Hon. Gregory M. Sleet |
Sensipar® (cinacalcet HCl tablets) |
9,375,405 |
| Aurobindo Pharma USA Inc. v. Andrx Corp., IPR2017-01673 (PTAB) |
23-Jun-17 |
N/A |
Fortamet® (metformin HCl extended-release tablets) Actoplus® Met XR (metformin HCl / pioglitazone HCl extended-release tablets) |
6,790,459 |
| Biogen Int’l GMBH v. Amneal Pharms. LLC, 17-0823 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 7,619,001 7,803,840 8,399,514 |
| Biogen Int’l GMBH v. Aurobindo Pharma U.S.A., Inc., 17-0824 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Hetero USA Inc., 17-0825 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen MA Inc. v. Impax Labs., Inc., 17-0826 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Prinston Pharm. Inc., 17-0827 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Slayback Pharma LLC, 17-0828 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen Int’l GMBH v. Teva Pharms. USA, Inc., 17-0829 (D. Del.) |
26-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Concert Pharms., Inc. v. Incyte Corp., PGR2017-00034 (PTAB) |
27-Jun-17 |
N/A |
Jakafi® (ruxolitinib phosphate tablets) |
9,662,335 |
| Biogen MA Inc. v. MSN Labs. Private Ltd, 17-0845 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Graviti Pharms Pvt. Ltd, 17-0846 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Shilpa Medicare Ltd., 17-0847 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Sun Pharma Global FZE, 17-0848 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen MA Inc. v. Windlas Healthcare, Pvt. Ltd., 17-0849 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
8,399,514 |
| Biogen Int’l GMBH v. Alkem Labs. Ltd., 17-0850 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Cipla Ltd., 17-0851 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Glenmark Pharms. Ltd., 17-0852 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Lupin Atlantis Holdings SA, 17-0853 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Torrent Pharms. Ltd., 17-0854 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Pharmathen S.A., 17-0855 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. TWi Pharms., Inc., 17-0856 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Macleods Pharms., Ltd., 17-0857 (D. Del.) |
28-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Sebela Int’l Ltd. v. Actavis Labs. FL, Inc., 17-4789 (D.N.J.) |
28-Jun-17 |
Hon. Claire C. Cecchi |
Brisdelle® (paroxetine capsules) |
9,393,237 |
| Biogen Int’l GMBH v. Stason Pharms., Inc., 17-1133 (C.D. Cal.) |
30-Jun-17 |
Hon. Douglas F. McCormick |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. Sandoz Inc., 17-1606 (D. Col.) |
30-Jun-17 |
Hon. Michael E. Hegarty |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Forest Labs., LLC v. Sun Pharma Global FZE, 17-0865 (D. Del.) |
30-Jun-17 |
Hon. Richard G. Andrews |
Linzess® (linaclotide capsules) |
8,933,030 |
| Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 17-0867 (D. Del.) |
30-Jun-17 |
Hon. Richard G. Andrews |
Afinitor® (everolimus tablets) |
5,665,772 |
| Biogen Int’l GMBH v. Accord Healthcare Inc., 17-0872 (D. Del.) |
30-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Par Pharm., Inc., 17-0873 (D. Del.) |
30-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Sandoz Inc., 17-0874 (D. Del.) |
30-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Sawai USA, Inc., 17-0875 (D. Del.) |
30-Jun-17 |
Hon. Leonard P. Stark |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
| Biogen Int’l GMBH v. Accord Healthcare Inc., 17-0612 (M.D.N.C.) |
30-Jun-17 |
Hon. William L. Osteen, Jr. |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Zydus Pharms. (USA) Inc., 17-4857 (D.N.J.) |
30-Jun-17 |
Hon. Brian R. Martinotti |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Par Pharm., Inc., 17-4984 (S.D.N.Y.) |
30-Jun-17 |
Hon. Jesse M. Furman |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
7,320,999 8,399,514 |
| Biogen Int’l GMBH v. Mylan Pharms. Inc., 17-0116 (N.D.W.V.) |
30-Jun-17 |
Hon. Irene M. Keeley |
Tecfidera® (dimethyl fumarate delayed-release capsules) |
6,509,376 7,320,999 7,619,001 7,803,840 8,759,393 8,399,514 |
Counsel
